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Abstract
Plasma membrane vesicles isolated from HeLa cells grown in suspension culture contain a protein disulfide-thiol
 .interchange protein disulfide-like activity. The activity was estimated from the restoration of activity to inactive
 .scrambled pancreatic RNAase. RNAase activity was measured either by hydrolysis of cCMP or by a decrease in acid
 .precipitable yeast RNA. The ability of plasma membrane vesicles to restore activity to inactive scrambled pancreatic
 . X  .  .ribonuclease was inhibited by the antitumor sulfonylurea N- 4-methylphenylsulfonyl -N - 4-chlorophenyl urea LY181984 .
The activity correlated with that of a cyanide-resistant NADH oxidase also associated with the plasma membrane vesicles
that exhibited a similar pattern of drug response. The activity was stimulated by reduced glutathione and inhibited by
oxidized glutathione but did not depend on either for activity. The antitumor sulfonylurea-inhibited activity was greatest in
the presence of reduced glutathione and least in the presence of oxidized glutathione. The antitumor sulfonylurea-inhibited
activity was unaffected by a monoclonal antibody to protein disulfide isomerase. Also the antitumor sulfonylurea-inhibited
activity was unaffected by peptide antisera to the consensus active site sequence of protein disulfide isomerase. Thus the
antitumor sulfonylurea-inhibited activity appeared to reside with a novel cell surface protein capable of oxidation of both
NADH and protein thiols and of carrying out a protein disulfide isomerase-like protein disulfide-thiol interchange activity in
the absence of NADH or other external reductants.
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1. Introduction
Homogenates, total particulate fractions and plasma
membranes of cultured HeLa S cells bound the triti-
w3 x w ated antitumor sulfonylurea H LY181984 N- 4-
. X  . xmethylphenyl -N - 4-chlorophenyl urea with high
 . w xaffinity K of 20 to 50 nM 1 . Highest affinityd
binding was to purified plasma membranes K of 25d
. w xnM . In a subsequent report 2 , a binding protein,
apparently with one or more thiols in the active site,
was identified and labeled with radioactive thiol
reagents in antitumor sulfonylurea protection experi-
ments. Binding proteins of M ca. 34 kDa werer
w xlabeled 2 .
w xBy analogy with earlier findings in plants 3 , the
binding activity was suggested to correlate with a 34
w xkDa drug-inhibited NADH oxidase 4 . An NADH
oxidase activity of the plant plasma membrane had
been reported to respond to auxin regulators of plant
w xgrowth 3 and to be drug-inhibited by herbicidal
w xsulfonylureas 5 active, as well, as plant growth
w xretardants 6 . However, the plasma membrane NADH
oxidase of plants was resistant not only to inhibition
by cyanide but also proceeded in an argon atmo-
w xsphere 7 . These findings prompted us to seek elec-
tron acceptors other than oxygen for the NADH
oxidation. During the course of these studies, an
ability of the plasma membranes to catalyze a protein
disulfide isomerase-like protein disulfide-thiol ex-
w xchange activity was revealed 7 . This activity of the
plant plasma membranes was stimulated by auxin
regulators of plant growth in parallel to the oxidation
w xof NADH 8 . In this report, we demonstrate an
ability of isolated plasma membrane vesicles from
HeLa cells to catalyze a protein disulfide-thiol ex-
change activity. The activity, like the NADH oxidase
w xof the HeLa plasma membrane 4 , is inhibited by the
antitumor sulfonylurea LY181984, but not by a struc-
turally-related but antitumor-inactive sulfonylurea,
 . X  .N - 4-m ethylphenylsulfonyl -N - phenyl urea
 .LY181985 . The drug responsiveness of the HeLa
activity provides an important parallel between the
protein disulfide-thiol interchange activity and that of
the NADH oxidase of the plasma membrane. The
latter was growth factor- and hormone-stimulated
with rat liver plasma membranes as well as resistant
w xto cyanide 9,10 . Upon transformation, the growth
factor- and hormone-responsiveness of the plasma
w xmembrane NADH oxidase appeared to be lost 11,12 .
The response to sulfonylurea provided an important
additional line of evidence of the existence in mam-
malian plasma membranes of a protein with both
NADH oxidase and protein disulfide-thiol inter-
change activities altered in transformation.
The sulfonylureas represent a novel series of syn-
thetic organic compounds identified as having activ-
w xity against human solid tumors in vivo 13–15 .
Known collectively as antitumor diarylsulfonylureas
 .sulfonylureas , the compounds have a high degree of
w xefficacy and a relatively low toxicity 13,15 . Addi-
tionally, their mechanism of action, while unknown,
is apparently unrelated to previously described classes
w xof oncolytic agents 16 . One member of the series,
w xSulofenur, progressed in evaluation to Phase I 15,16
w xand Phase II 17 clinical trials. The sulfonylureas
were identified as the result of a program of screen-
ing against in vivo murine solid tumors implanted
w xsubcutaneously 14 .
Despite considerable clinical and laboratory data,
the site of antitumor sulfonylurea action has remained
w xelusive 13,18 . The drugs were membrane active and
weak uncouplers of mitochondrial oxidative phospho-
w xrylation 18–21 , a response given by sulfonylureas
w xboth active and inactive as antitumor agents 21 .
There was no evidence for cell cycle specificity of
the drugs and no inhibition of DNA, RNA or protein
w xsynthesis 16,18 . The sulfonylureas exhibited few, if
any, mechanistic parallels to other known antitumor
w xagents 22 . Their mode of action was expected to be
unique and, as shown by the present study, appears to
involve inhibition of a cell-surface protein disulfide-
thiol interchange protein with NADH oxidase activ-
ity.
2. Materials and methods
2.1. Growth of cells
HeLa S cells were grown on Minimal Essential
 .  .Medium S-MEM Joklik modified with glutamine
 .  .244 mgrl and phosphate 1.3 grl Na HPO and2 4
without CaCl plus 5% donor horse serum. Gen-2
 . tamycin sulfate 50 mgrl and sodium bicarbonate 2
.grl were added.
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2.2. Purification of plasma membranes from HeLa
cells
HeLa cells grown as suspension cultures were
collected by centrifugation for 6 min at 1 000=g.
The cell pellets were resuspended in 0.2 mM EDTA
in 1 mM NaHCO in an approximate ratio of 1 ml3
per 108 cells and incubated on ice for 10 to 30 min to
swell the cells. Homogenization was with a Polytron
homogenizer for 40 sec at 10 000 rpm using a 10
ST-probe and 7 ml aliquots. To estimate breakage,
the cells were monitored by light microscopy before
and after homogenization. At least 90% cell breakage
without breakage of nuclei was achieved routinely.
The homogenates were centrifuged for 10 min at
175=g to remove unbroken cells and nuclei and the
supernatant was centrifuged a second time at 15 000
=g to prepare a plasma membrane-enriched micro-
some fraction. The supernatant was discarded and the
pellets were resuspended in 0.2 M potassium phos-
phate buffer in a ratio of approximately 1 ml per
pellet from 5P108 cells. The resuspended membranes
then were loaded onto the two-phase system consti-
tuted on a weight basis as follows. The two-phase
 .system contained 6.6% wrw Dextran T-500
 .  .  .Pharmacia , 6.6% wrw poly ethylene glycol 3350
 . Fisher , and 0.2 M potassium phosphate buffer pH
. w x  .7.2 23 . The homogenate 2 g was added to the
two-phase system and the weight of the system was
brought to 16 g with distilled water. The tubes were
 .inverted vigorously for 40 times in the cold 48C .
The phases were separated by centrifugation at 750
 .rpm 150=g in a Sorvall HB 4 rotor for 5 min. The
upper phases were carefully withdrawn with a Pas-
teur pipette, divided in half and transferred into 40 ml
plastic centrifuge tubes and diluted with cold l mM
NaHCO and centrifuged at 10 000=g in a HB rotor3
for 30 min. The purity of the plasma membrane was
determined to be )90% by electron microscope
morphometry. The yield was 20 mg plasma mem-
brane protein from 1010 cells.
2.3. Estimation of protein disulfide-thiol interchange
acti˝ity
Two methods were employed to determine protein
disulfide-thiol interchange activity. Both involved
restoration of ribonuclease activity by refolding of
 .reduced and randomly oxidized scrambled and ini-
tially inactive ribonuclease A.
 .In the first method Method I , restoration of activ-
ity to ribonuclease A activity was measured using a
spectrophotometric assay based on hydrolysis of
w xcCMP as the RNAase substrate 24 . Scrambled
 .RNAase 0.36 mg was incubated together with 0.45
 .mM cCMP in 50 mM Tris-Mes buffer pH 6.5 , at
308C in a final volume of 3 ml. In the absence of
membranes, the scrambled RNAase was inactive 2%
.of the native RNAase . In the presence of mem-
branes, the scrambled RNAase became active as evi-
denced from an increase in A from the RNAase296
catalyzed hydrolysis of cCMP. A variation of this
assay was to preincubate scrambled RNAase with
HeLa plasma membranes for 20 min in the presence
or absence of 1 mM LY181984 added as a DMSO
 .solution using DMSO as control and in the presence
or absence of 1 mM reduced or oxidized glutathione
or a mixture of both. After this 20 min of reactivation
of RNAase, cCMP was added to a final concentration
of 0.45 mM to initiate the reaction. The increase of
the absorbance at 296 nm was recorded over 25 min
and the concentrations of cCMP were determined
 y1 y1.es0.19 mM cm . Measurements were with a
Hitachi U3210 spectrophotometer with a ther-
mostated cell compartment maintained at 308C with
continuous stirring.
 .The second method Method II followed the pro-
w xcedure of Kalnitsky et al. 25 where the rate of
hydrolysis of yeast RNA was determined by measur-
ing the amount of acid-soluble oligonucleotides liber-
ated. Here, 250 ml of 0.15 mM sodium acetate buffer
 .pH 7.0 , 550 ml of reagent grade water, 10 ml of
 .HeLa plasma membranes 140 to 180 mg protein
and 50 ml of scrambled or reduced RNAase 0.36
.mg were preincubated in a 1.5 ml Eppendorf cen-
trifuge tube for 20 min at 378C. For the assay, 100 ml
was transferred to each of 4 tubes. Yeast RNA 100
. ml, 0.33 mgrml, pH 5.0 was added. After 0 two
.  .tubes and 10 min two tubes , the reaction was
stopped by the addition of 100 ml of 25% perchloric
acid containing 0.75% uranyl acetate. The tubes were
cooled in an ice bath for 5 min and clarified by
 .centrifugation 2 min, microfuge . Then 75 ml of the
clear supernatant from each tube was diluted to 3.0
ml with water. The absorbance was determined at
260 nm against an unincubated blank. The ab-
( )D.J. Morre et al.rBiochimica et Biophysica Acta 1325 1997 117–125´120
sorbance at 0 min averaged from the two determina-
tions was then subtracted from the absorbance at 10
min averaged from the two determinations. One unit
was defined as an increase in absorbance of 1.0 at
A at 378C and pH 5.0.260
Protein was estimated by the method of Smith et
w xal. 26 with bovine serum albumin as the standard.
2.4. Preparation of scrambled RNAase substrate
To prepare the oxidized, denatured RNAase sub-
 . strate scrambled RNAase , native RNAase A Sigma,
.  .Type 1-AS from bovine pancreas 30 mgrml was
incubated 1 h at 358C in 50 mM Tris-acetate pH
. w x8.6 , containing 9 M urea and 130 mM DTT 27 .
The fully reduced protein was isolated by adjusting
the pH to 4.0 with glacial acetic acid followed by
elution from a column of Sephadex G-25 with de-
gassed 0.1 M acetic acid and used directly or further
processed to produce scrambled RNAase. Protein
concentration was estimated from spectrophotometric
measurement at 280 nm using native RNAase A as
standard. For preparation of scrambled RNAase, the
reduced RNAase was diluted to ;0.5 mgrml with
0.1 M acetic acid. Solid urea then was added to a
final concentration of 10 M after which 0.1 M sarco-
sine hydrochloride was added and the pH adjusted to
8.5 with 1 M Tris. The mixture then was incubated in
the dark for 2–3 days during which time the protein
was randomly oxidized. The scrambled product was
recovered by acidification to pH 4 with glacial acetic
acid and elution from Sephadex G-25 in 0.1 M acetic
acid. Fractions containing protein were pooled, ad-
justed to pH 8 and stored at 48C. Free thiol groups, as
X  . w xdetermined using 5,5 -dithio 2-nitrobenzoic acid 28 ,
were 80 to 90% oxidized.
2.5. Source of antisera
Antiprotein disulfide isomerase antibody was a
 .mouse monoclonal antibody SPA-891 from Stress-
 .Gen Biotechnologies Victoria, Canada . The im-
munogen was protein disulfide isomerase purified
from bovine liver and the antisera cross-reacted with
protein disulfide isomerase from human, monkey, rat,
mouse and hamster cell lines. The peptide antibody
was to Cys-Tyr-Ala-Pro-Trp-Cys-Gly-His-Cys-Lys-
Gln-Leu-Ala-Pro-Ile conjugated to keyhole limpet
hemocyanin and supplied as whole rabbit sera. The
peptide was synthesized and the antisera prepared by
 .Immuno-Dynamics, La Jolla, CA Antisera a1472 .
The preimmune sera were from the same source as
the peptide antisera.
3. Results
w xWhen estimated using cCMP as substrate 26
 .Method I , HeLa plasma membranes restored activ-
 .ity to scrambled RNAase Table 1 . Restoration of
Table 1
 .Protein disulfide-thiol interchange activity of HeLa plasma membranes Method I
Treatment nmolrmin per mg protein Change due to LY181984
LY181984 total
aNone None 36"4 y25
b1 mM 11"8
c .1 mM reduced glutathione GSH None 75"4 y37
a1 mM 38"3
a .1 mM oxidized glutathione GSSG None 26"8 y 8
b1 mM 18"6
cGSHqGSSG None 72"24 y53
b1 mM 19"8
dScrambled RNAase – 8"3
All treatments contained 360 mg scrambled RNAase and 200 mg HeLa plasma membrane protein except for scrambled RNAase alone
where the plasma membranes were omitted.
 .Numbers not followed by the same letters were significantly different from each other P-0.02 as determined by two-tailed t-test. The
 .inhibitions by LY181984 with no additions and in the presence of GSH were highly significant P-0.001 .
Results are averages of three determinations, each with a different preparation of plasma membranes"S.D. Specific activities are based
on plasma membrane protein.
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RNAase activity was accelerated by addition of 1
 .mM reduced glutathione GSH and was slowed by 1
 .  .mM oxidized glutathione GSSG Table 1 . Restora-
tion of activity to scrambled RNAase by HeLa plasma
membranes was inhibited by 1 mM LY181984. When
corrected for activity in the absence of plasma mem-
branes, the inhibition by LY181984 was between 80
and 90% in the absence of GSH or GSSG or with
GSH and GSSG in equal proportions. The increment
of sulfonylurea-inhibited activity was greatest with
GSH alone or an equal mixture of GSH and GSSG
 .and was least with GSSG alone Table 1 .
The concentration dependency of the sulfonylurea
 .inhibition exhibited an EC of about 30 nM Fig. 1 .50
The sulfonylurea was added as a DMSO solution
 .final DMSO concentration 0.1% . DMSO controls
were evaluated and the solvent, on average, was
without effect. Also without effect was LY181985, a
homolog of LY181984 inactive as an antitumor agent,
at concentrations equivalent to those for the antitu-
 .mor-active LY181984 Fig. 1 .
When RNAase was assayed by the Kalnitsky et al.
w x  .method 25 Method II , plasma membranes of HeLa
cells also exhibited a protein disulfide-thiol inter-
change activity as evidenced by the restoration of
 .activity to scrambled RNAase Table 2 . This activity
 .was stimulated by 1 mM reduced glutathione GSH
and was inhibited by 1 mM LY181984. This method
Fig. 1. Response to sulfonylurea concentration of the protein
disulfide-thiol interchange activity of HeLa plasma membranes.
The activity was inhibited when treated with the active antitumor
sulfonylurea LY181984 but not by the inactive sulfonylurea
LY181985. The specific activity is calculated after 20 min of
reactivation on the basis of the amount of plasma membrane
protein in the assay.
provided a more direct assay of ribonuclease activity
based on the hydrolysis of acid-precipitable RNA.
 .As with Method I Table 1 , the increment of
Table 2
 .Effect of sulfonylurea and thiol compounds on protein disulfide-thiol interchange of HeLa plasma membranes Method II
 .Addition 1 mM LY181984 Ar20 min
total change due to LY181984
aNone None 0.041"0.006 y0.012
b1 mM 0.029"0.003
aDMSO None 0.034"0.001 y0.008
b1 mM 0.026"0.005
a,c .1 mM reduced glutathione GSH None 0.049"0.002 y0.014
a,b1 mM 0.035"0.004
a,b .1 mM oxidized glutathione GSSG None 0.036"0.005 y0.003
b1 mM 0.033"0.002
aGSHqGSSG None 0.051"0.003 y0.016
a,b1 mM 0.035"0.003
bScrambled RNAase – 0.024"0.004
All treatments contained 360 mg scrambled RNAase and 200 mg HeLa plasma membrane except for scrambled RNAase alone where the
plasma membranes were omitted.
 .Numbers not followed by the same letters were significantly different as determined by two-tailed t-test P-0.05 . Results are averages
of 3–6 determinations, each with a different preparation of plasma membranes"S.D. Specific activities are based on plasma membrane
protein.
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Table 3
Effect of sulfonylureas and thiol compounds on activity of native
RNAase at pH 6.0 and pH 6.8
Sulfonylurea nmolrmin per mg
pH 6.0 pH 6.8
None 150 210
1 mM LY181984 140 210
1 mM LY181985 150 210
Assay was by Method I.
sulfonylurea inhibition determined by Method II was
greatest with GSH present or with a balanced redox
system containing both GSH and GSSG compared to
DMSO alone and was least in the presence of GSSG
 .alone Table 2 . The blank rate was determined to be
the same both in the presence and absence of GSH or
w xGSSG 28 and was unaffected by DMSO or
LY181984. There was no effect of LY181984 alone
 .on active RNAase Table 3 .
The activity inhibited by the antitumor sulfonyl-
urea LY181984 appeared not to be that of a classic
protein disulfide isomerase. Under conditions where
the activity of authentic protein disulfide isomerase
was inhibited by the antisera, monoclonal antisera to
authentic protein disulfide isomerase or polyclonal
antisera to a consensus peptide sequence of protein
disulfide isomerase containing the active site cys-
teines both failed to inhibit the protein disulfide-thiol
interchange activity of HeLa plasma membranes in-
hibited by LY181984 as determined either by Method
Table 4
Response to antisera directed to protein disulfide isomerase of the protein disulfide-thiol interchange activity stimulated by reduced
 .glutathione GSH and inhibited by LY181984 of HeLa plasma membranes by Method I
Antisera nmolrmin per mg protein
no GSH no GSHq 1 mM GSH 1 mM GSHq
1 mM LY181984 1 mM LY181984
a a a aNone 35"2 9"3 72"3 38"3
b a a,b bPreimmune 25"3 4"2 63"8 29"4
a,b a b aPeptide antisera 1472 30"5 6"2 60"5 40"4
a b b a,bAnti-PDI MAB 36"3 18"3 55"7 39"8
 .StressGen SPA-891
Antisera were added to 3 ml of the assay mixture containing ca. 200 mg of HeLa plasma membrane protein at a final dilution 1:2 400.
Following a 20 min preincubation with antisera plus plasma membranes and scrambled RNAase, the cCMP substrate was added to initiate
the reaction.
 .Numbers not followed by the same letter were significantly different P-0.02 as determined by two-tailed t-test. Results are averages
of three determinations"S.D. Specific activities were based on plasma membrane protein.
Table 5
Inhibition by the antitumor sulfonylurea LY181984 of the protein disulfide-thiol interchange activity of HeLa plasma membranes assayed
 .  .by Method II in the presence of 1 mM reduced GSH or oxidized GSSG glutathione
GSHrGSSG Antisera Sulfonylurea inhibition
 .Ar20 min
None None 0.011"0.003
Peptide AB 1472 0.009"0.002
MAB SPA-891 0.013"0.004
 .1 mM reduced glutathione GSH None 0.01"0.002
Peptide AB 1472 0.006"0.004
MAB SPA-891 0.011
 .1 mM oxidized glutathione GSSG None 0.003"0.001
Peptide AB 1472 0.002"0.002
MAB SPA-891 0.004
Conditions were as for Table 2. Results with anti-PDI peptide antisera 1472 were from three experiments. The values for Anti-PDI MAB
 .StressGen SPA-891 were from a single experiment of triplicate determinations each. Inhibition of activity by the sulfonylurea in the
presence of antisera were not significantly different from those in the absence of antisera.
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 .  .I Table 4 or by Method II Table 5 . The peptide
antisera and preimmune sera were approximately
equal in their effect. With both the antisera to the
active site peptide and the monoclonal antibody to
protein disulfide isomerase, the component of activity
inhibited by LY181984 was unaffected by either
antisera as determined using either Method I Table
.  .4 or using Method II Table 5 either in the presence
or absence of reduced glutathione. Although not sig-
nificant statistically, the activity in the presence of
reduced glutathione was reduced in the presence of
 .antisera compared to no antisera Table 4 .
4. Discussion
Protein disulfide isomerase or protein disulfide
isomerase-like enzymes are multifunctional proteins
that catalyze disulfide-thiol interchange reactions in
protein substrates leading to net protein disulfide
reduction, formation or isomerization, or thiol oxida-
tion depending on the initial substrates and the thiol-
disulfide potential imposed by the environment e.g.,
. w xthe redox buffer 29 . More recently, protein disul-
fide isomerase-like activity has been reported to be
associated with plasma membranes of cultured mam-
w xmalian cells 30 . In this report, we demonstrate a
protein disulfide isomerase-like activity using plasma
membrane vesicles isolated from HeLa cells that
appears to be distinct from classical protein disulfide
isomerases of the endoplasmic reticulum lumen and
that is responsive to the antitumor sulfonylureas.
Protein disulfide isomerase activities are normally
assayed by the ability of these proteins to catalyze
w xrefolding of proteins that contain disulfide bonds 31 .
For example, in a glutathione redox buffer, protein
disulfide isomerases function catalytically to regener-
ate native RNAase from the oxidized form at the
w xexpense of reducing equivalents from GSH 24 .
In the present report, we have utilized two differ-
ent methods to assay protein disulfide isomerase-like
or protein disulfide-thiol interchange activity of HeLa
plasma membranes and the response of the activity to
sulfonylureas. The active antitumor sulfonylurea
LY181984 inhibited the refolding of RNAase de-
pending on the redox buffer and conditions of prein-
cubation. With no preincubation or with membranes
preincubated with GSH or a mixture of GSH and
GSSG, LY181984 inhibited the activation of scram-
bled RNAase. The findings suggest that the response
to LY181984 was influenced by the imposed thiol-
disulfide potential as generated by the surrounding
redox buffer. However, even if the redox state was
unbalanced, either with GSH or GSSG alone, sul-
fonylurea inhibitions were still observed.
A response similar to that of the sulfonylurea-in-
hibited protein disulfide-thiol interchange activity was
observed previously with 2,4-D-stimulated NADH
w xoxidase activity and growth 32 . However, the 2,4-
D-stimulated activity was blocked in the presence of
unbalanced GSH or GSSG.
That the protein disulfide-thiol interchange activity
responded to sulfonylurea even in the absence of
GSH, GSSG or GSHqGSSG argued against the
disulfide-thiol interchange activity being obligatorily
driven by reducing equivalents coming from reduced
glutathione. Thus the activity inhibited by sulfony-
lurea appeared to be distinct from the classic protein
disulfide isomerase of the endoplasmic reticulum lu-
men and also distinct from an oxidoreductase activity
obligatorily driven by pyridine nucleotide substrates
such as glutathione reductase which requires NADPH,
for example.
To become reactivated, the interchain disulfides of
the scrambled RNAase must first be reduced under
conditions favorable for renaturation and then be-
come reoxidized under renaturing conditions to re-
form the interchain disulfides in a correct conforma-
tion to restore catalytic activity. In the process of
protein disulfide-thiol interchange catalyzed by HeLa
plasma membranes, the rate of activation of scram-
bled RNAase appears to follow a sigmoid function
with an early accelerating rate and a declining later
w xrate 8 . In the absence of GSH or GSSG, the source
of disulfides and thiols to reactivate the RNAase is
presumably protein disulfides and thiols of the plasma
membrane as the reactivation takes place in the ab-
sence of any other external thiol, disulfide or reduced
pyridine nucleotide source.
The increment of sulfonylurea inhibition was
greatest with GSH present or with a mixture of GSH
and GSSG and least with GSSG alone for both
Method I and Method II. This agrees with an earlier
w3 xobservation that binding of H LY181984 to HeLa
cell plasma membranes was enhanced under reducing
w xand much less under oxidizing conditions 1 . The
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enhanced total activity, however, observed as a result
 .of GSH or GSHqGSSG addition Tables 1 and 2
may not necessarily reflect the sulfonylurea-inhibited
activity but may be a contribution coming from a
sulfonylurea-resistant activity also associated with the
plasma membrane that was enhanced by GSH. The
HeLa plasma membranes contain both sulfonylurea-
resistant and sulfonylurea-susceptible components of
NADH oxidase activity that respond differently to
w xdrugs and thiol reagents 4,33 . The constitutive
NADH oxidase activity was stimulated by GSH in rat
liver, for example, whereas the activity in trans-
 . w xformed e.g. HeLa cells was not 33 . A similar
differential response exhibited by the protein disul-
fide-thiol interchange activity could account as well
for the stimulations by GSH reported here.
The significance of a protein disulfide-thiol inter-
change activity associated with the plasma membrane
and modulated by antitumor sulfonylureas cannot yet
be decided with certainty. Specificity is indicated
from the observation that the antitumor-inactive sul-
fonylurea LY181985 that differs from LY181984 by
w xa single chlorine on the B ring 13 was without
effect in inhibiting the thiol interchange-catalyzed
reactivation of scrambled yeast RNAase. The
LY181985 was ineffective at several log orders more
sulfonylurea than was necessary to inhibit with
LY181984.
In these experiments, a strong correlation exists
among the inhibition of protein disulfide-thiol inter-
change of HeLa cell plasma membranes or whole
 .cells Fig. 1 , of NADH oxidase activity of HeLa cell
w xplasma membranes 4 , of diferric transferrin- or
ferricyanide-induced proton efflux in intact HeLa
w xcells 34 and of HeLa cell growth in the presence of
w xEGF 35 . All were inhibited with an EC of about50
30 nM which agrees closely with the kDa for binding
w3 xof H LY181984 to isolated vesicles of HeLa plasma
w xmembranes of about 30 nM 1 . Thus a reasonable
supposition would be that the sulfonylurea-inhibited
protein disulfide-thiol interchange activity and the
sulfonylurea-inhibited NADH oxidation may repre-
sent two different manifestations of the activity of the
same sulfonylurea-binding protein of the HeLa cell
plasma membrane.
The sulfonylurea-inhibited activity of the protein
disulfide-thiol interchange activity was unaffected by
a monoclonal antibody to protein disulfide isomerase
purified from bovine liver. The antibody cross-re-
acted with human protein disulfide isomerase, yet did
not block the sulfonylurea-inhibited protein
disulfide-like activity of the HeLa plasma mem-
branes. Also, antisera prepared to a synthetic peptide
corresponding to the highly conserved consensus re-
gion containing the active site of human protein
w xdisulfide isomerase 36,37 failed to inhibit. We do
not rule out the possibility of an association of pro-
tein disulfide isomerase with the mammalian plasma
membrane. The component of the protein disulfide-
thiol interchange activity stimulated by GSH and
resistant to inhibition by LY181984 might represent
such an activity. However, the failure of the antipro-
tein disulfide isomerase antisera to eliminate the sul-
fonylurea-inhibited activity, taken together with a
lack of dependency of activity on the presence of
reduced glutathione, suggest the sulfonylurea-in-
hibited protein disulfide-thiol interchange activity of
the HeLa plasma membrane to be an activity distinct
from that of a classical protein disulfide isomerase of
the endoplasmic reticulum lumen.
If, indeed, the sulfonylurea-inhibited NADH oxi-
dase protein is able to catalyze protein disulfide-thiol
interchange, then it follows that the activity may be
able to catalyze the net reduction of disulfides or the
net oxidation of thiols as well under appropriate
conditions of incubation i.e., function as a disulfide
.oxidoreductase . As such it could carry out important
functions in the membrane related either to protein
disulfide-thiol interchange or to net thiol content and
obligatorily unrelated either to NADH oxidation or to
the operation of a plasma membrane redox chain per
 w x.se see also 38 .
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